{"id":483973,"date":"2020-05-12T12:46:01","date_gmt":"2020-05-12T12:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483973"},"modified":"2020-05-12T12:46:01","modified_gmt":"2020-05-12T12:46:01","slug":"retinitis-pigmentosa-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/retinitis-pigmentosa-market-insights-epidemiology-and-market-forecast2030_483973.html","title":{"rendered":"Retinitis Pigmentosa Market Insights, Epidemiology and Market Forecast-2030"},"content":{"rendered":"
\"Retinitis<\/a><\/p>\n
\n
DelveInsight<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Retinitis Pigmentosa Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

DelveInsight launched a new report on Retinitis Pigmentosa Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

Some of the key facts of the report<\/span>
– In 2017, the diagnosed Retinitis Pigmentosa prevalent population in the 7Major Markets were 253,420.<\/span>
– The diagnosed Retinitis Pigmentosa prevalence was 108,787 in the US in 2017.<\/span>
– Among the EU-5 countries, Germany had the highest Retinitis Pigmentosa diagnosed prevalent population of 30,642 cases.<\/span><\/p>\n

Key benefits of the report<\/span>
1. Retinitis Pigmentosa Market report covers a descriptive overview and comprehensive insight of the Retinitis Pigmentosa epidemiology and Retinitis Pigmentosa market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span>
2. Retinitis Pigmentosa market report provides insights on the current and emerging therapies.<\/span>
3. Retinitis Pigmentosa market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/span>
4. Retinitis Pigmentosa market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Retinitis Pigmentosa market.<\/span><\/p>\n

Request for sample pages<\/a><\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

Current there are no standard Retinitis Pigmentosa treatments available for patients. However, Retinitis Pigmentosa treatments are available for a sporadic form and managing some aspects of its clinical manifestations with other new treatments involving gene therapy, transplantation, and implanted electrical devices, being in active development.<\/span><\/p>\n

The diagnosis, prognosis, and management of Retinitis Pigmentosa continue to be challenging in current practice. This is related to an incomplete understanding of the pathophysiology of the disease process, complexity due to the involvement of several genes, and a lack of evidence-based standardized curative therapies for all forms of Retinitis Pigmentosa in significant geographies. To-date, the role of various genes and their associated mutations have been implicated. However, the pathophysiology of the Retinitis Pigmentosa remains poorly understood.<\/span><\/p>\n

The outlook for Retinitis Pigmentosa treatments is promising. Various clinical trials for gene therapy and stem cell therapy have been relatively positive in terms of safety and limited evaluations of efficacy. The results of these studies are encouraging further investigation into the basic physiology of the retina, as well as the mechanisms of effective prevention and reversal of inherited retinal degenerations.<\/span><\/p>\n

The launch of the emerging therapies is expected to significantly impact Retinitis Pigmentosa treatment scenario in the upcoming years:-<\/span>
Drugs covered<\/span>
1. HORA-RPE65<\/span>
2. jCell<\/span>
3. AGN-151597<\/span>
4. Cenegermin<\/span>
5. Renexus<\/span>
6. hRPC<\/span>
And many others<\/span><\/p>\n

The key players in Retinitis Pigmentosa market are:<\/span>
1. Horama<\/span>
2. jCyte<\/span>
3. Allergan<\/span>
4. Dompé Farmaceutici<\/span>
5. Neurotech Pharmaceuticals<\/span>
6. ReNeuron Limited<\/span>
And many others<\/span><\/p>\n

Table of contents<\/span><\/p>\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Retinitis Pigmentosa<\/span><\/p>\n

3. Retinitis Pigmentosa Market Overview at a Glance<\/span><\/p>\n

4. Retinitis Pigmentosa Disease Background and Overview<\/span><\/p>\n

5. Case Reports<\/span><\/p>\n

6. Retinitis Pigmentosa Epidemiology and Patient Population<\/span><\/p>\n

7. United States Epidemiology<\/span><\/p>\n

8. EU5 Epidemiology<\/span><\/p>\n

8.1. Germany Epidemiology<\/span><\/p>\n

8.2. France Epidemiology<\/span><\/p>\n

8.3. Italy Epidemiology<\/span><\/p>\n

8.4. Spain Epidemiology<\/span><\/p>\n

8.5. United Kingdom Epidemiology<\/span><\/p>\n

9. Japan Epidemiology<\/span><\/p>\n

10. Retinitis Pigmentosa Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

11. Proposed Guidelines for Retinitis Pigmentosa<\/span><\/p>\n

12. Unmet Needs<\/span><\/p>\n

13. Retinitis Pigmentosa Marketed Products<\/span><\/p>\n

13.1.Luxturna: Spark Therapeutics\/ Novartis<\/span><\/p>\n

14. Emerging Therapies<\/span><\/p>\n

14.2.HORA-RPE65: Horama<\/span><\/p>\n

14.3.HORA-PDE6B: Horama<\/span><\/p>\n

14.4.AAV8-RPGR\/BIIB112: Nightstar Therapeutics\/Biogen<\/span><\/p>\n

14.5.jCell: jCyte<\/span><\/p>\n

14.6.Renexus: Neurotech<\/span><\/p>\n

14.7.Cenegermin: Dompé Farmaceutici<\/span><\/p>\n

14.8.hRPC Cells : ReNeuron<\/span><\/p>\n

14.9.UshStat: Sanofi (Terminated)<\/span><\/p>\n

14.10. AGN-151597: Allergan<\/span><\/p>\n

14.11.AAV-RPGR: MeiraGTx<\/span><\/p>\n

14.12. AAV-RPE65: MeiraGTx<\/span><\/p>\n

15. Retinitis Pigmentosa 7MM Market Analysis<\/span><\/p>\n

16. United States: Market Outlook<\/span><\/p>\n

16.1.United States Market Size<\/span><\/p>\n

17. EU-5 countries: Market Outlook<\/span><\/p>\n

17.1.Germany Market Size<\/span><\/p>\n

17.2.France Market Size<\/span><\/p>\n

17.3.Italy Market Size<\/span><\/p>\n

17.4.Spain Market Size<\/span><\/p>\n

17.5.United Kingdom Market Size<\/span><\/p>\n

18. Japan Market Outlook<\/span><\/p>\n

18.1.Japan Market Size<\/span><\/p>\n

19. Access and Reimbursement Overview of Retinitis Pigmentosa<\/span><\/p>\n

20. Market Drivers<\/span><\/p>\n

21. Market Barriers<\/span><\/p>\n

22. SWOT Analysis<\/span><\/p>\n

23. Appendix<\/span><\/p>\n

24. DelveInsight Capabilities<\/span><\/p>\n

25. Disclaimer<\/span><\/p>\n

26. About DelveInsight<\/span><\/p>\n

About DelveInsight<\/span>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/span><\/p>\n

Contact us:<\/span>
info@delveinsight.com<\/span>
+919650213330<\/span>
SOURCE DelveInsight<\/span><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight DelveInsight’s “Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Retinitis Pigmentosa , historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-483973","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483973"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}